Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 19/20 | 1.00 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.60 |
| ▸ | C1R | P00736 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19189656 | 0.82 | ELANE (0.70) | ELANECTRB1 | |
| SCHEMBL23881485 | 0.82 | ELANE (0.70) | ELANECTRB1 | |
| SCHEMBL4119409 | 0.82 | ELANE (0.70) | ELANEC1R | |
| SCHEMBL8543622 | 0.82 | ELANE (0.70) | ELANECTRB1C1R | |
| SCHEMBL8016730 | 0.81 | ELANE (0.76) | ELANECTRB1C1R | |
| SCHEMBL10069984 | 0.80 | ELANE (0.66) | ELANECTRB1 | |
| SCHEMBL13206696 | 0.80 | ELANE (1.00) | ELANEC1R | |
| SCHEMBL10362711 | 0.80 | ELANE (1.00) | ELANECTRB1 | |
| SCHEMBL8006834 | 0.80 | C1R (0.81) | ELANEC1R | |
| SCHEMBL10657051 | 0.80 | ELANE (1.00) | ELANECTRB1C1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115677803-B | Preparation method of glycoside derivative containing quinazoline structure and composition thereof and application of glycoside derivative and composition for preventing and treating kiwi fruit canker | 贵州理工学院 | 2025-03-28 | — | — | CN | disclosed |
| CN-115521262-B | Preparation method of quinazolinone containing phenyl and composition thereof, and application of quinazolinone and composition in resisting kiwi fruit canker | 贵州理工学院 | 2024-04-05 | — | — | CN | disclosed |
| CN-115521261-B | Preparation method of mercapto-containing quinazolinone and composition thereof, and application of mercapto-containing quinazolinone in resisting kiwi fruit canker | 贵州理工学院 | 2024-04-05 | — | — | CN | disclosed |
| US-11820720-B2 | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deuteropiperidine-2,6-dione derivatives and compositions comprising and methods of using the same | SALARIUS PHARMACEUTICALS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820720-B2 | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deuteropiperidine-2,6-dione derivatives and compositions comprising and methods of using the same | SALARIUS PHARMACEUTICALS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| CN-115677803-A | Preparation method of glucoside derivative containing quinazoline structure, preparation method of composition of glucoside derivative and application of composition in prevention and treatment of kiwifruit canker | 贵州理工学院 | 2023-02-03 | — | — | CN | disclosed |
| CN-115521261-A | Preparation method of sulfhydryl-containing quinazolinone and composition thereof and application of sulfhydryl-containing quinazolinone in resisting kiwifruit canker | 贵州理工学院 | 2022-12-27 | — | — | CN | disclosed |
| CN-115521262-A | Preparation method of phenyl-containing quinazolinone and composition thereof and application of phenyl-containing quinazolinone in resisting kiwifruit canker | 贵州理工学院 | 2022-12-27 | — | — | CN | disclosed |
| US-11040925-B2 | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same | DEUTERX, LLC (US) | 2021-06-22 | — | — | US | disclosed |
| EP-2943201-B2 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES | DEUTERX LLC (US) | 2020-07-29 | — | — | EP | disclosed |
| US-20100093774-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION. | 2010-04-15 | — | — | US | disclosed |
| US-7635700-B2 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | CELGENE CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| US-20090209562-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| EP-2066656-A2 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS | CELGENE CORPORATION (US) | 2009-06-10 | — | — | EP | disclosed |
| US-7521455-B2 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| US-20080161328-A1 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | CELGENE CORPORATION | 2008-07-03 | — | — | US | disclosed |
| WO-2008039489-A2 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS | CELGENE CORPORATION (US) | 2008-04-03 | — | — | WO | disclosed |
| EP-1717230-A1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| US-20060229324-A1 | Quinazolin-4-one derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-10-12 | — | — | US | disclosed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820720-B2 | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deuteropiperidine-2,6-dione derivatives and compositions comprising and methods of using the same | IL5, IL15, CXCR5 | ELANE 1051/4885CTRB1 4558/4885C1R 3517/4885 |
| US-11040925-B2 | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same | IL5, TLR5, IDO1 | ELANE 1346/4885CTRB1 4776/4885C1R 3319/4885 |
| US-20080161328-A1 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | FGF2, TNF, FGF1 | ELANE 134/4885CTRB1 2081/4885C1R 4596/4885 |
| US-20060229324-A1 | Quinazolin-4-one derivatives | HPGDS, PTGS1, PTGDR | ELANE 1046/4885CTRB1 2904/4885C1R 523/4885 |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | ELANE 4447/4885CTRB1 2172/4885C1R 472/4885 |
| US-20090209562-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | ELANE 4447/4885CTRB1 2172/4885C1R 472/4885 |
| US-20100093774-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, IL6, PGF | ELANE 1183/4885CTRB1 606/4885C1R 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.